To date, treatment with LEU011 has been generally well tolerated. In addition, disease control (based on RECIST criteria) has been observed in multiple patients treated with the lowest dose of LEU011.
Dr. Stephen Schoenberger, a professor at La Jolla Institute for Immunology, explores how recent discoveries and emerging ...
Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data ...
ME Therapeutics Holdings Inc., a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of ...
T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
DuoCAR20.19.22-D95 targets CD19, CD20, and CD22, addressing antigen escape in B-cell malignancies like B-ALL and B-NHL. Early-stage trials show no safety concerns for DuoCAR20.19.22-D95, with ongoing ...
Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal worth as much as $2 billion. The pact is with Adaptive Biotechnologies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback